Trial Profile
A Phase II, Open-Label, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2011
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; MF 59
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis Vaccines
- 18 Nov 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 18 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2009 New trial record